Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shun Lu

Showing results (451-460 of 661) with videos related to

Pageof 67
Sort By:
Frontiers in Immunology|December 13, 2021
Predictable Roles of Peripheral IgM Memory B Cells for the Responses to Anti-PD-1 Monotherapy Against Advanced Non-Small Cell Lung CancerLiliang Xia, Limin Guo, Jin Kang, et al.
Ebiomedicine|March 16, 2019
Value of folate receptor-positive circulating tumour cells in the clinical management of indeterminate lung nodules: A non-invasive biomarker for predicting malignancy and tumour invasivenessQianjun Zhou, Qing Geng, Lin Wang, et al.
Biorxiv : the Preprint Server for Biology|February 13, 2026
Spatial multi-omics unveils the monoclonal origin, neuroendocrine plasticity, and microenvironment niches in combined small cell lung cancerZhuo Wang, Qing Luo, Jie Wu, et al.
Science China. Life Sciences|February 1, 2021
Peripheral CD4<sup>+</sup> T cell signatures in predicting the responses to anti-PD-1/PD-L1 monotherapy for Chinese advanced non-small cell lung cancerLiliang Xia, Hui Wang, Mingjiao Sun, et al.
Annals of Surgical Oncology|August 16, 2023
Neoadjuvant Chemoimmunotherapy Increases Tumor Immune Lymphocytes Infiltration in Resectable Non-small Cell Lung CancerTianxiang Chen, Zhengqi Cao, Yingjia Sun, et al.
Cell Reports. Medicine|April 12, 2026
Spatial multi-omics unveils the monoclonal origin, neuroendocrine plasticity, and microenvironment niches in combined small-cell lung cancerZhuo Wang, Qing Luo, Jie Wu, et al.
Oncotargets and Therapy|December 26, 2018
Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring <i>EGFR</i> mutations: subgroup analysis of the LUX-Lung 6 trialYi-Long Wu, Chong-Rui Xu, Cheng-Ping Hu, et al.
Iscience|January 10, 2022
Convergent alteration of lung tissue microbiota and tumor cells in lung cancerHui Dong, Qiang Tan, Yuanyuan Xu, et al.
Eclinicalmedicine|July 1, 2021
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trialGlenwood D Goss, Manuel Cobo, Shun Lu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2024
Efficacy and Safety of Roxadustat for Anemia in Patients Receiving Chemotherapy for Nonmyeloid Malignancies: A Randomized, Open-Label, Active-Controlled Phase III StudyShun Lu, Jiong Wu, Jin Jiang, et al.
Pageof 67

Showing results (451-460 of 661) with videos related to

Sort By:
Pageof 67
Frontiers in Immunology|December 13, 2021
Predictable Roles of Peripheral IgM Memory B Cells for the Responses to Anti-PD-1 Monotherapy Against Advanced Non-Small Cell Lung CancerLiliang Xia, Limin Guo, Jin Kang, et al.
Ebiomedicine|March 16, 2019
Value of folate receptor-positive circulating tumour cells in the clinical management of indeterminate lung nodules: A non-invasive biomarker for predicting malignancy and tumour invasivenessQianjun Zhou, Qing Geng, Lin Wang, et al.
Biorxiv : the Preprint Server for Biology|February 13, 2026
Spatial multi-omics unveils the monoclonal origin, neuroendocrine plasticity, and microenvironment niches in combined small cell lung cancerZhuo Wang, Qing Luo, Jie Wu, et al.
Science China. Life Sciences|February 1, 2021
Peripheral CD4<sup>+</sup> T cell signatures in predicting the responses to anti-PD-1/PD-L1 monotherapy for Chinese advanced non-small cell lung cancerLiliang Xia, Hui Wang, Mingjiao Sun, et al.
Annals of Surgical Oncology|August 16, 2023
Neoadjuvant Chemoimmunotherapy Increases Tumor Immune Lymphocytes Infiltration in Resectable Non-small Cell Lung CancerTianxiang Chen, Zhengqi Cao, Yingjia Sun, et al.
Cell Reports. Medicine|April 12, 2026
Spatial multi-omics unveils the monoclonal origin, neuroendocrine plasticity, and microenvironment niches in combined small-cell lung cancerZhuo Wang, Qing Luo, Jie Wu, et al.
Oncotargets and Therapy|December 26, 2018
Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring <i>EGFR</i> mutations: subgroup analysis of the LUX-Lung 6 trialYi-Long Wu, Chong-Rui Xu, Cheng-Ping Hu, et al.
Iscience|January 10, 2022
Convergent alteration of lung tissue microbiota and tumor cells in lung cancerHui Dong, Qiang Tan, Yuanyuan Xu, et al.
Eclinicalmedicine|July 1, 2021
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trialGlenwood D Goss, Manuel Cobo, Shun Lu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2024
Efficacy and Safety of Roxadustat for Anemia in Patients Receiving Chemotherapy for Nonmyeloid Malignancies: A Randomized, Open-Label, Active-Controlled Phase III StudyShun Lu, Jiong Wu, Jin Jiang, et al.
Pageof 67